Floatz logo

Pembrolizumab

Stage IVb Bladder Cancer

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Stage IVb Bladder Cancer cohort.

Asset / SponsorPhaseRating
Nivolumab
M.D. Anderson Cancer Center
Phase 2B
Atezolizumab
M.D. Anderson Cancer Center
Phase 2B
Relatlimab
M.D. Anderson Cancer Center
Phase 2CCC
Glycosylated Recombinant Human Interleukin-7
National Cancer Institute (NCI)
Phase 2CCC
Durvalumab
M.D. Anderson Cancer Center
Phase 1/2CCC

View all 12 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →